Myriad Genetics Acquires Melanoma Technology | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market on Wednesday that it has reached an agreement to acquire technology from Melanoma Diagnostics for the diagnosis and prognosis of malignant melanoma using genetic markers.

Myriad has the global right to commercialize all tests based on the technology. In exchange, Melanoma Diagnostics will receive upfront fees and payments contingent on the commercial success of the products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.